Cytodyn Inc (CYDY) 0.8550 $CYDY
CytoDyn To Expand Clinical Applications For PRO 140 Beyond Therapy For HIV
PRWeb - Wed Jun 24, 10:40PM CDT
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer.
CytoDyn to Expand Clinical Applications for PRO 140 Beyond Therapy for HIV
GlobeNewswire - Wed Jun 24, 5:30AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer.
CytoDyn starts Phase 3 for injectable antibody for HIV infection
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 6:56AM CDT
PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
CytoDyn Cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
GlobeNewswire - Tue Jun 09, 5:29AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has initiated its first Phase 3 study for PRO 140, the Company's novel self-injectable antibody for the treatment of HIV. The Company's Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients. Selection of clinical sites, IRB approvals, patients screening and other administrative matters are underway and are expected to be completed in time for the first patient to be dosed in the third quarter of this year.
HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 6.35 (+0.02), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ARGS: 6.45 (+0.69), INO: 7.46 (+0.19), JNJ: 99.53 (+1.13), ENZ: 3.00 (+0.04), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57)
CytoDyn Submits Phase 3 Protocol to FDA for HIV Trial; Conference Call on May 5
PRWeb - Mon May 04, 10:00PM CDT
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has reached an agreement with the FDA on the Company's previously submitted Phase 3 protocol synopsis for PRO 140, the Company's novel self-injectable antibody for the treatment of HIV, and submitted the full Phase 3 protocol to the FDA today. The Company's Phase 3 protocol provides for a 25-week study with 300 HIV patients, which could start as early as 30 days after submission.
CytoDyn Submits Phase 3 Protocol to FDA After Agreement on Protocol Synopsis
GlobeNewswire - Mon May 04, 3:05PM CDT
Six Months of Monotherapy With PRO 140 Has Been Effective for HIV Patients in Phase 2b Study
S&P Capital IQ Initiates Coverage on CytoDyn Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Tue Feb 10, 10:55AM CST
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on CytoDyn Inc.
MHFI: 103.16 (+2.27)
CytoDyn Announces Successful Phase2b Clinical Trial Results for HIV Antibody Treatment
PRWeb - Tue Feb 03, 10:02PM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140. After the conclusion of the initial 14-week study, CytoDyn agreed to allow 14 patients to continue on the monotherapy in an extension study. A few patients have now progressed to nearly 6 months of successful PRO 140 monotherapy.
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy - Many HIV Patients in Extension Study With Some Approaching 6 Months
GlobeNewswire - Tue Feb 03, 7:45AM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140. After the conclusion of the initial 14-week study, CytoDyn agreed to allow 14 patients to continue on the monotherapy in an extension study. A few patients have now progressed to nearly 6 months of successful PRO 140 monotherapy.
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.41 (+0.33), VTAE: 10.26 (-0.25), XNCR: 22.60 (+0.13)
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program
GlobeNewswire - Mon Nov 24, 7:01AM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its company information is now available via S&P Capital IQ Corporation Records Listing Program. As part of the program, a full description of CytoDyn will be published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial
GlobeNewswire - Mon Oct 13, 7:00AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced the continuation of strong positive results for four weeks of monotherapy with its monoclonal antibody, PRO 140, in patients with HIV-1, who are currently participating in the Company's Phase 2b treatment substitution trial. Management will hold an investment community conference call on October 14, 2014, at 1:00 p.m. PT to discuss the ongoing Phase 2b treatment substitution clinical trial results and the upcoming "end of Phase 2b meeting" with the FDA.
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIV
GlobeNewswire - Fri Oct 10, 3:26PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Tuesday, October 14, 2014 at 1:00 p.m. PT to discuss the results from its ongoing Phase 2b treatment substitution clinical trial in patients with HIV.
CytoDyn Appoints Carl Dockery to Board of Directors
GlobeNewswire - Wed Oct 01, 2:43PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced the appointment of Carl Dockery to its Board of Directors effective September 26, 2014. Mr. Dockery is a financial executive with over 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC.
CytoDyn Announces Webcast for Annual Shareholder Meeting
GlobeNewswire - Fri Aug 15, 2:06PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its August 20, 2014 annual meeting of shareholders will be shared live through a webcast that will allow the public to access the audio portion of the meeting, as well as management's presentation.
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Thu Jul 31, 7:21AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced positive interim results from its Phase 2b treatment substitution study. The Company will hold an investment community conference call on August 4, 2014, at 9:00 a.m. PT to discuss the trial's protocol, clinical results, and anticipated path forward, as well as to address questions from the call's participants.
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Wed Jul 30, 8:52PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Monday, August 4, 2014 at 9:00 a.m. PT to discuss the interim results from its ongoing Phase 2b treatment substitution study in patients with HIV.
CytoDyn To Expand Clinical Applications For PRO 140 Beyond Therapy For HIV
PRWeb - Wed Jun 24, 10:40PM CDT
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer.
CytoDyn to Expand Clinical Applications for PRO 140 Beyond Therapy for HIV
GlobeNewswire - Wed Jun 24, 5:30AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that recent Company research data has expanded the potential clinical indications for PRO 140, now in Phase 3 for the treatment of HIV, to include certain inflammatory diseases, autoimmunity, transplantation and cancer.
CytoDyn starts Phase 3 for injectable antibody for HIV infection
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 6:56AM CDT
PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
CytoDyn Cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
GlobeNewswire - Tue Jun 09, 5:29AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has initiated its first Phase 3 study for PRO 140, the Company's novel self-injectable antibody for the treatment of HIV. The Company's Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients. Selection of clinical sites, IRB approvals, patients screening and other administrative matters are underway and are expected to be completed in time for the first patient to be dosed in the third quarter of this year.
HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 6.35 (+0.02), PFE: 34.36 (+0.50), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), ARGS: 6.45 (+0.69), INO: 7.46 (+0.19), JNJ: 99.53 (+1.13), ENZ: 3.00 (+0.04), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57)
CytoDyn Submits Phase 3 Protocol to FDA for HIV Trial; Conference Call on May 5
PRWeb - Mon May 04, 10:00PM CDT
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has reached an agreement with the FDA on the Company's previously submitted Phase 3 protocol synopsis for PRO 140, the Company's novel self-injectable antibody for the treatment of HIV, and submitted the full Phase 3 protocol to the FDA today. The Company's Phase 3 protocol provides for a 25-week study with 300 HIV patients, which could start as early as 30 days after submission.
CytoDyn Submits Phase 3 Protocol to FDA After Agreement on Protocol Synopsis
GlobeNewswire - Mon May 04, 3:05PM CDT
Six Months of Monotherapy With PRO 140 Has Been Effective for HIV Patients in Phase 2b Study
S&P Capital IQ Initiates Coverage on CytoDyn Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Tue Feb 10, 10:55AM CST
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on CytoDyn Inc.
MHFI: 103.16 (+2.27)
CytoDyn Announces Successful Phase2b Clinical Trial Results for HIV Antibody Treatment
PRWeb - Tue Feb 03, 10:02PM CST
CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140. After the conclusion of the initial 14-week study, CytoDyn agreed to allow 14 patients to continue on the monotherapy in an extension study. A few patients have now progressed to nearly 6 months of successful PRO 140 monotherapy.
CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy - Many HIV Patients in Extension Study With Some Approaching 6 Months
GlobeNewswire - Tue Feb 03, 7:45AM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that it had concluded its Phase 2b treatment substitution study and reported 39 patients out of 40 participating in the study passed 4 weeks of monotherapy with PRO 140. After the conclusion of the initial 14-week study, CytoDyn agreed to allow 14 patients to continue on the monotherapy in an extension study. A few patients have now progressed to nearly 6 months of successful PRO 140 monotherapy.
Cellceutix Overvalued By 90-99%
Ben Sharvy - at Seeking Alpha - Fri Jan 02, 4:21PM CST
VNDA: 12.41 (+0.33), VTAE: 10.26 (-0.25), XNCR: 22.60 (+0.13)
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program
GlobeNewswire - Mon Nov 24, 7:01AM CST
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its company information is now available via S&P Capital IQ Corporation Records Listing Program. As part of the program, a full description of CytoDyn will be published in the Daily News Section of Standard & Poor's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial
GlobeNewswire - Mon Oct 13, 7:00AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced the continuation of strong positive results for four weeks of monotherapy with its monoclonal antibody, PRO 140, in patients with HIV-1, who are currently participating in the Company's Phase 2b treatment substitution trial. Management will hold an investment community conference call on October 14, 2014, at 1:00 p.m. PT to discuss the ongoing Phase 2b treatment substitution clinical trial results and the upcoming "end of Phase 2b meeting" with the FDA.
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIV
GlobeNewswire - Fri Oct 10, 3:26PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Tuesday, October 14, 2014 at 1:00 p.m. PT to discuss the results from its ongoing Phase 2b treatment substitution clinical trial in patients with HIV.
CytoDyn Appoints Carl Dockery to Board of Directors
GlobeNewswire - Wed Oct 01, 2:43PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced the appointment of Carl Dockery to its Board of Directors effective September 26, 2014. Mr. Dockery is a financial executive with over 30 years of experience as an executive in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC.
CytoDyn Announces Webcast for Annual Shareholder Meeting
GlobeNewswire - Fri Aug 15, 2:06PM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its August 20, 2014 annual meeting of shareholders will be shared live through a webcast that will allow the public to access the audio portion of the meeting, as well as management's presentation.
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Thu Jul 31, 7:21AM CDT
CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced positive interim results from its Phase 2b treatment substitution study. The Company will hold an investment community conference call on August 4, 2014, at 9:00 a.m. PT to discuss the trial's protocol, clinical results, and anticipated path forward, as well as to address questions from the call's participants.
CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV
GlobeNewswire - Wed Jul 30, 8:52PM CDT
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that the Company will host a live conference call and webcast with the investment community on Monday, August 4, 2014 at 9:00 a.m. PT to discuss the interim results from its ongoing Phase 2b treatment substitution study in patients with HIV.
